A murine–human chimeric IgG antibody against vascular endothelial growth factor receptor 2 inhibits angiogenesis in vitro

Abstract

Vascular endothelial growth factor receptor 2 (VEGFR2) has been reported to play an important role in angiogenesis and tumorigenesis. A murine anti-VEGFR2 mAb (A8H1) has been established in a previous study. To reduce the incompatibility of the murine mAb for human use, the chimeric anti-VEGFR2-IgG was developed by genetic recombination of the variable regions of the A8H1 antibody and the constant regions of human IgG, and was expressed in Sp2/0 cells transfected with the two recombinant vectors containing the heavy chain and the light chain regions. After screening, clone 2F12 was selected and was found to stably secrete the murine-human chimeric anti-VEGFR2-IgG (coded 2F12). This chimeric IgG maintained the specificity and the affinity of the parental murine antibody against VEGFR2, and effectively identified VEGFR2 expressed on the surface of HUVECs and BEL-7402 cells. Furthermore, the 2F12 antibody demonstrated inhibition of angiogenesis in vitro, such as proliferation, migration, invasion and tube formation of HUVECs. This murine-human chimeric IgG may be considered for further development as an anti-angiogenesis and anti-tumor agent.

Lysine as a potential low molecular weight angiogen: its clinical, experimental and in-silico validation- A brief study

“…Since, tumor angiogenesis or uncontrolled non-hierarchical angiogenesis play central role in proliferation of cancerous cells, the area of angiogenesis is mainly governed by studies on the inhibition of the process [9][10][11][12][13][14] . In addition, the absence of a good candidate molecule as an effective mediator of induced angiogenic process the field of induced controlled augmented angiogenesis is substantially on a low key in the current global research trend.…”